Access to anti-retroviral drugs, male in Jordan

Jordan: Access to anti-retroviral drugs, male was 64.0% in 2024. ▲ Rising

Latest (2024)
64.0%
Change on year
up 14.3%
World rank
87th
of 141 countries
All-time high
64.0%
in 2024
All-time low
13.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Jordan, 2000–2024

2040602000201220242000: 13 %2001: 15 %2002: 16 %2003: 16 %2004: 16 %2005: 21 %2006: 22 %2007: 26 %2008: 28 %2009: 33 %2010: 36 %2011: 36 %2012: 39 %2013: 39 %2014: 38 %2015: 39 %2016: 45 %2017: 48 %2018: 53 %2019: 56 %2020: 58 %2021: 43 %2022: 48 %2023: 56 %2024: 64 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Jordan is 64.0%, measured in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 14.3% on the previous year and up 68.4% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Jordan peaked at 64.0% in 2024 and was at its lowest, 13.0%, in 2000.

That places Jordan 87th out of 141 countries with data for 2024, putting it in the middle of the range.

The long-run direction has been consistently rising across the 25 years of available data.

Access to anti-retroviral drugs, male in Jordan, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Jordan, 2000 to 2024.
Year % Change
2000 13.0%
2001 15.0% +15.4%
2002 16.0% +6.7%
2003 16.0% +0.0%
2004 16.0% +0.0%
2005 21.0% +31.2%
2006 22.0% +4.8%
2007 26.0% +18.2%
2008 28.0% +7.7%
2009 33.0% +17.9%
2010 36.0% +9.1%
2011 36.0% +0.0%
2012 39.0% +8.3%
2013 39.0% +0.0%
2014 38.0% -2.6%
2015 39.0% +2.6%
2016 45.0% +15.4%
2017 48.0% +6.7%
2018 53.0% +10.4%
2019 56.0% +5.7%
2020 58.0% +3.6%
2021 43.0% -25.9%
2022 48.0% +11.6%
2023 56.0% +16.7%
2024 64.0% +14.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 20.6% 13.0% 33.0% 10
2010s 42.9% 36.0% 56.0% 10
2020s 53.8% 43.0% 64.0% 5

Countries ranked near Jordan

  1. 87 Cape Verde 64.0% compare
  2. 87 Colombia 64.0% compare
  3. 87 Guinea 64.0% compare
  4. 87 Mali 64.0% compare

See the full ranking of 160 places →

More gender data for Jordan

All data for Jordan →

Frequently asked questions

What is access to anti-retroviral drugs, male in Jordan?
Access to anti-retroviral drugs, male in Jordan was 64.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Jordan?
The highest recorded value was 64.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Jordan?
The lowest recorded value was 13.0% in 2000.
How does Jordan rank for access to anti-retroviral drugs, male?
Jordan ranks 87th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Jordan?
Over the last ten years it is up 68.4%. The long-run trend across the full record is rising.
Where does this Jordan data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Jordan. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/jordan/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/jordan/">Access to anti-retroviral drugs, male in Jordan</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.